```json
{
"content": [
{
"type": "list",
"title": "Growth Drivers",
"items": [
{
"text": "Increased R&D investments in biopharmaceuticals are expanding Prostaglandin E2’s applications in chronic inflammatory diseases and ophthalmology, directly influencing the Prostaglandin E2 market size.",
"level": 1
},
{
"text": "Rising adoption in emerging economies, driven by improving healthcare infrastructure and rising awareness of specialty therapeutics, is accelerating demand and reshaping the Prostaglandin E2 market growth forecast.",
"level": 1
}
]
},
{
"type": "list",
"title": "Restraints",
"items": [
{
"text": "High synthesis complexity and associated production costs limit scalability, particularly for small manufacturers competing in price-sensitive regions.",
"level": 1
},
{
"text": "Stringent regulatory approval timelines in Europe and Japan delay product launches, creating bottlenecks for market expansion.",
"level": 1
}
]
},
{
"type": "list",
"title": "Opportunities",
"items": [
{
"text": "Advancements in precision medicine are opening niche applications for Prostaglandin E2 in personalized oncology therapies, unlocking new revenue streams.",
"level": 1
},
{
"text": "Strategic partnerships between biotech firms and API suppliers are optimizing R&D efficiency and reducing time-to-market for innovative Prostaglandin E2 formulations.",
"level": 1
}
]
},
{
"type": "list
